<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1B14F69F-D4D5-42F0-B730-AF3EED034C16"><gtr:id>1B14F69F-D4D5-42F0-B730-AF3EED034C16</gtr:id><gtr:firstName>Davis</gtr:firstName><gtr:surname>Nwakanma</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U190092708"><gtr:id>B32365D3-194E-48C8-BE9B-1B1311719005</gtr:id><gtr:title>Molecular methods for anti-malarial drug resistance surveillance: evolution of CQ/pyrimethamine-sulphadoxine resistance</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U190092708</gtr:grantReference><gtr:abstractText>The ability of malaria parasites to develop resistance to previously effective drugs is a major impediment to malaria control. With the introduction of effective but expensive anti-malaria treatment using Co-artem (co-atemether and lumefantrine) it is important to monitor malaria parasites for the emergence of drug resistance. The standard method for assessing drug efficacy is by measuring how patients respond to drug treatment. However, it is now recognised that molecular methods that detect changes in the parasite genes responsible for drug resistance could serve as complementary tools for drug resistance surveillance. We are using molecular methods to analyze archived blood samples collected in malaria surveys in the Farafenni area of Gambia from 1984 to 2008. Parasite DNA isolated from malaria-positive samples will be screened to detect changes in genes that cause resistance to two previously effective anti-malarial drugs, Chloroquine (CQ) and Pyrimethamine-Sulphadoxine (SP). This study will help to establish a method that can routinely screen large number of samples in a malaria surveillance system generating data to inform malaria treatment policy and improve our understanding of how malaria parasites that are resistant to anti-malarial drugs increase and become established in the population.</gtr:abstractText><gtr:technicalSummary>The resistance of Plasmodium falciparum to the cheap and affordable anti-malarial drugs, Chloroquine (CQ) and Pyrimethamine-Sulphadoxine (SP), has led to adoption of Artemisinin-based combination therapy (ACT), as first-line treatment for malaria. To protect these new anti-malarial drugs, a system to monitor the emergence and spread of drug resistance is needed. Although the standard method for determining drug efficacy is by measuring the clinical responses of patients to drug treatment, molecular markers have been recognised as potentially powerful tools for surveillance of anti-malarial drug resistance and could provide early warning signals of impending drug failure as genotypic resistance precedes parasitological and clinical resistance. Routine screening of parasite isolates from sentinel sites for drug resistance should be a major component of any malaria surveillance system. In preparation for the establishment of prospective drug resistance surveillance in The Gambia, we are analyzing archived blood samples collected in cross sectional malaria surveys conducted in the Farafenni area of The Gambia spanning a period of over twenty years from 1984 to 2008. Using both classical restriction analysis of PCR amplified gene products (PCR-RFLP) and a real-time PCR assay that offers the advantage of increased assay throughput, parasite DNA isolated from malaria-positive blood samples collected in 1984, 1988, 1991, 2001, 2004 and 2008 (~ 100 from each time point) will be genotyped at loci associated with resistance to the anti-malarial drugs Chloroquine (CQ) and Sulphadoxine-Pyrimethamine (SP). Preliminary results show progressive increase in frequency of alleles of different parasite genes that cause Chloroquine and Sulphadoxine-Pyrimethamine resistance. Over this time, the Pfcrt allele 76T (encoding threonine at amino acid position 76) has increased from undetectable levels to near fixation. We are also investigating the alleles of the parasite gene Pfcrt in more detail to reveal if the resistance is from the same genetic source as has been described elsewhere in Africa, by determining the complete coding sequence and if the flanking microsatellite loci have the same alleles that mark the common resistance haplotype. Results will be analysed to determine the rate of change in allele frequencies and estimate the selective coefficients over this historical time. The project should provide important information on the previous evolution of anti-malarial drug resistance in this region and the practicalities of establishing high throughput assays for molecular genotyping of drug resistance as part of a malaria surveillance system.</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-06-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>780205</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The Royal Society of Tropical Medicine &amp;amp; Hygiene Centenary Scholarship 2009/The Royal Society of Tropical Medicine &amp;amp; Hygiene Centenary Scholarship</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>Royal Society of Tropical Medicine and Hygiene (RSTMH)</gtr:fundingOrg><gtr:id>D93C83C8-5C87-4634-9A38-A059E6F76970</gtr:id><gtr:outcomeId>UZUSUCpey9p0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>BE1E9BCA-F3EA-4DF0-B968-E369D26C0175</gtr:id><gtr:title>Changes in malaria parasite drug resistance in an endemic population over a 25-year period with resulting genomic evidence of selection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d17217a91ffab5a3cc6df8fd797dcf4"><gtr:id>8d17217a91ffab5a3cc6df8fd797dcf4</gtr:id><gtr:otherNames>Nwakanma DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>DV2Kenf24Zd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C726F5F0-D4B7-4CA6-BFD3-4FB40A422843</gtr:id><gtr:title>Diagnostic performance of a novel loop-mediated isothermal amplification (LAMP) assay targeting the apicoplast genome for malaria diagnosis in a field setting in sub-Saharan Africa.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88aeefcf1cc9ae70f541d487bd9b6528"><gtr:id>88aeefcf1cc9ae70f541d487bd9b6528</gtr:id><gtr:otherNames>Oriero EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>56d71710bfd1d3.36000135</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U190092708</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>